Data delays – a real-time challenge for clinical trials in Pharma

Delayed clinical trial data delivery is a growing problem for pharmaceutical companies and one that can have catastrophic consequences for the development of their promising pipeline candidates.

When data delivery lags behind the pace of a clinical study it means that data entry will be delayed – especially if the data arrives in multiple formats or from a number of different sources that then need to be reconciled.

The upshot of these issues can be a series of serious setbacks, as clearing redundant data becomes different and programming complex edit checks becomes next to impossible.

As illustrated in a new infographic from Remarque Systems (scroll down to see it), delays with the delivery of clinical trial data are a growing problem across the pharmaceutical industry, with important ramifications for studies in a number of areas, including personalized medicine.

The clinical trial optimization company says that while delays in data transfer from external and internal partners have long been an expected inconvenience in the course of a clinical trial, the situation is quickly becoming untenable as the amount and variety of trial-related data multiples.

Where researches are unable to view or verify data they face errors, delays, inefficiencies and costs that should be entirely avoidable, Remarque Systems says.

A lack of real-time access to all of the available clinical trial data also means that clearing redundant data becomes difficult, and programming complex edit checks becomes impossible.

When it comes to accessing their clinical data, the majority of respondents in a 2018 Pharma Intelligence survey said they did not have real-time access to their data, which can cause problems that can go undetected until it is too late.

The pharmaceutical industry faces continual pressure to optimize clinical trials, maximize returns and minimize risk. Better data quality can improve decision-making, making companies more informed, shrinking trial timelines and costs, and securing patient safety.





























































The Transformational Impact of Artificial Intelligence on the Patient-Physician Relationship

In today’s ever-evolving healthcare landscape, the integration of artificial intelligence (AI) has ushered in a new era of possibilities, presenting…

What is Medical Communications? The definitive guide.

Medical Communications. The demand for clear and integrated dissemination of scientific knowledge is critical for the Pharmaceutical industry. Medical communications—or…

Enhancing engagement with healthcare professionals (HCPs): How AI is transforming Pharma relationships.

Pharmaceutical companies are progressively turning to the use of Artificial Intelligence (AI) as a tool to transform several aspects of…

Six communication trends Pharma needs to watch in 2024.

As we approach 2024, the Pharma industry’s focus on developing and maintaining meaningful relationships with healthcare professionals (HCPs) will only…

The EU Artificial Intelligence Act: A New Era of Regulation 
The EU's proposed AI Act, the world's first comprehensive legal framework for AI, is set to revolutionize global AI regulation. Learn about its risk classification levels and the potential implications for the Life Sciences industry.
0 +



0 +




0 +



Whether you’re looking for effective solutions to transition F2F meetings to a virtual or online environment, support with clinical trials, medical advisory boards, symposia, key opinion leader (KOL) management, internal medical training, medical writing or speaker training programs and more, count on our 16-year experience and expertise over 40 therapeutic areas.

SDM also offers strategic consulting services and can help with communication and engagement of your target audiences as part of market development opportunities.

Discover why over 95% of clients are “Extremely Satisfied” with SDM and over 90% say the agency deliver “Much more than expected”.